Ascletis Pharma, Inc. (HK:1672) has released an update.
Ascletis Pharma Inc. revealed promising Phase I study results for its innovative weight loss drug, ASC47, showcasing significant fat reduction and muscle preservation compared to existing treatments. The study in Australia highlighted ASC47’s potential for once-monthly administration due to its 21-day half-life and impressive tolerance profile with minimal adverse effects. These findings position ASC47 as a compelling candidate in the obesity treatment market, with further studies underway.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend
- Amazon Considers Additional Multi-Billion Dollar Investment in Anthropic
- Will Palantir Stock Crash by 50%? Here’s What Jefferies Expects
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
